AIV Logo AIV Assistant

Loading...

 Logo Theraclion SA - ALTHE.PA Open Theraclion SA in new tab

0.71 EUR
EPS
-0.08
P/B
18.16
ROE
-118.70
Beta
0.06

0.7060 EUR

0.706 EUR

Daily: +92.37%
Key Metrics

Earnings date: April 27, 2026

EPS: -0.08

Book Value: 0.02

Price to Book: 18.16

Debt/Equity: 34.48

% Insiders: 30.222%

Growth

Revenue Growth: 2.32%

Estimates

Forward P/E: 3.45

Forward EPS: 0.10

DCF Valuation

Tweak assumptions to recompute fair value for Theraclion SA (ALTHE.PA)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

 Logo About Theraclion SA - (ALTHE.PA)

Country: France

Sector: Health Care

Website: http://www.theraclion.com

Theraclion SA develops echotherapy solutions using high intensity focused ultrasound system. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient's skin and optimizes the image quality. Theraclion SA was founded in 2004 and is based in Malakoff, France.

Exchange Ticker
PNK (United States) TCLIF
PAR (France) ALTHE.PA

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion